1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34.
|
2. |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
|
3. |
Walker MJ, Zhou C, Backen A, et al. Discovery and validation of predictive biomarkers of survival for non-small cell lung cancer patients undergoing radical radiotherapy: two proteins with predictive value. EBioMedicine, 2015, 2(8): 841-850.
|
4. |
Noonan SA, Patil T, Gao D, et al. Baseline and on-treatment characteristics of serum tumor markers in stage Ⅳ oncogene-addicted adenocarcinoma of the lung. J Thorac Oncol, 2018, 13(1): 134-138.
|
5. |
Kinoshita T, Ohtsuka T, Yotsukura M, et al. Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stageⅠadenocarcinoma and squamous cell carcinoma of the lung. J Thorac Oncol, 2015, 10(4): 619-628.
|
6. |
Holdenrieder S, Wehnl B, Hettwer K, et al. Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis. Br J Cancer, 2017, 116(8): 1037-1045.
|
7. |
Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 2009, 30(7): 1073-1081.
|
8. |
Wisastra R, Dekker FJ. Inflammation, cancer and oxidative lipoxygenase activity are intimately linked. Cancers (Basel), 2014, 6(3): 1500-1521.
|
9. |
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol, 2018, 9: 754.
|
10. |
Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial, 2004, 17(6): 432-437.
|
11. |
Pastorino U, Morelli D, Leuzzi G, et al. Baseline and postoperative C-reactive protein levels predict long-term survival after lung metastasectomy. Ann Surg Oncol, 2019, 26(3): 869-875.
|
12. |
Yang JR, Xu JY, Chen GC, et al. Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study. Sci Rep, 2019, 9(1): 8143.
|
13. |
McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis, 2007, 22(8): 881-886.
|
14. |
Schoenberg MB, Anger HJW, Hao J, et al. Development of novel biological resection criteria for safe and oncologically satisfying resection of hepatocellular carcinoma. Surg Oncol, 2018, 27(4): 663-673.
|
15. |
Walsh SM, Casey S, Kennedy R, et al. Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?. J Surg Oncol, 2016, 113(7): 732-737.
|
16. |
Wen J, Bedford M, Begum R, et al. The value of inflammation based prognostic scores in patients undergoing surgical resection for oesophageal and gastric carcinoma. J Surg Oncol, 2018, 117(8): 1697-1707.
|
17. |
Cox PR. The Aging of populations and its economic and social implications. Royal Statistical Society, 1958, 121(2): 253-254.
|
18. |
Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest, 2017, 151(1): 193-203.
|
19. |
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011, 144(5): 646-674.
|
20. |
Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol, 2012, 22(1): 33-40.
|
21. |
Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell, 2009, 15(2): 79-80.
|
22. |
Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol, 2012, 33(3): 119-126.
|
23. |
Cannon NA, Meyer J, Iyengar P, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol, 2015, 10(2): 280-285.
|
24. |
Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer, 2014, 111(3): 452-460.
|
25. |
Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol, 2018, 14(6): 402-409.
|
26. |
Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol, 2010, 28(16): 2719-2726.
|
27. |
Shiels MS, Katki HA, Hildesheim A, et al. Circulating inflammation markers, risk of lung cancer, and utility for risk stratification. J Natl Cancer Inst, 2015, 107(10): pii: djv199.
|
28. |
Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer, 2003, 89(6): 1028-1030.
|
29. |
Jin J, Hu K, Zhou Y, et al. Clinical utility of the modified Glasgow prognostic score in lung cancer: a meta-analysis. PLoS One, 2017, 12(9): e0184412.
|
30. |
Zhu L, Li X, Shen Y, et al. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Onco Targets Ther, 2016, 9: 4879-4886.
|
31. |
Pinato DJ, Shiner RJ, Seckl MJ, et al. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer, 2014, 110(8): 1930-1935.
|
32. |
Zhou T, Zhao Y, Zhao S, et al. Comparison of the prognostic value of systemic inflammation response markers in small cell lung cancer patients. J Cancer, 2019, 10(7): 1685-1692.
|
33. |
Leung EY, Scott HR, McMillan DC. Clinical utility of the pretreatment Glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol, 2012, 7(4): 655-662.
|
34. |
Kishi T, Matsuo Y, Ueki N, et al. Pretreatment modified Glasgow prognostic score predicts clinical outcomes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2015, 92(3): 619-626.
|